Case 1:07-cv-00229-GMS
Document 50
Filed 01/31/2008
Page 1 of 1
MORRIS, NICHOLS, ARSHT & TUNNELL
1201 N O R T H M A R K E T S T R EE T P.O. B O X 1347 W I L M I N G T O N , D E L A W A R E 19899-1347 302 658 9200 302 658 3989 F A X
M A R Y B. G R A H A M 302.351.9199 [email protected]
LLP
January 31, 2008
VIA ELECTRONIC FILING The Honorable Gregory M. Sleet United States District Court Federal Building 844 North King Street Wilmington, DE 19801 Re: Merck & Co., Inc. v. Ranbaxy Inc. and Ranbaxy Laboratories Limited C.A. No. 07-229
Dear Chief Judge Sleet: I am writing on behalf of the plaintiff, Merck & Co., Inc., regarding Defendants Ranbaxy Inc.'s and Ranbaxy Laboratories, Limited's Motion for Leave to Amend and Supplement its Answer, which was filed on January 11, 2008 (D.I. 48). Although Merck does not concede that any of Ranbaxy's proposed supplementations are proper, Merck does not oppose Ranbaxy's motion. Respectfully,
/s/ Mary B. Graham
Mary B. Graham (#2256) MBG/dam cc: Clerk of the Court (via hand delivery) Frederick L. Cottrell, Esquire (via email) Mark Boland, Esquire (via email) Raymond N. Nimrod, Esquire (via email)
1446027